Exonics Therapeutics receives $5m seed funding to advance Duchenne Muscular Dystrophy therapy

pharmanewsdaily- February 28, 2017 0

Exonics Therapeutics, a biotechnology firm based in Boston, Massachusetts, has secured $5 million in seed funding from CureDuchenne Ventures, a subsidiary of the nonprofit Duchenne ... Read More